You need a new shot every year because current flu vaccines provide limited and temporary protection. But researchers' new strategy could mean a one-and-done influenza vaccine...
Laboratory testing found antibody drug from Eli Lilly is inactive against South African Variant
The hormone acts as a barrier against SARS-CoV-2, blocking the expression of genes that encode proteins in cells serving as viral entry points, according to a...
Credit: Helmholtz Zentrum München Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University...
Credit: Professor Calum Semple A high proportion of survivors of Ebola experienced a resurgence in antibody levels nearly a year after recovery, a new University of...
Neutralising antibodies aren't the only game in town.
Eli Lilly said new data showed that treatment with 2 of its antibody therapies lowered COVID-19-related hospitalizations & deaths in high-risk patients by 70%.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir's investigational monoclonal antibody VIR-7831 in combination with Lilly’s bamlanivimab in low-risk patients with mild...
The UK government has claimed the new British variant of the coronavirus may be 30% more deadly.
AstraZeneca is playing catch up with Eli Lilly and Regeneron with its antibody therapy for COVID-19, but aims The post AZ deploys mobile sites to test...
Eli Lilly and Co. will move a new Covid-19 antibody therapy to human trials targeting a coronavirus variant that was first found in South Africa
Credit: Ulf Sirborn Individual variations in how the immune system responds to SARS-CoV-2 appear to impact the severity of disease. Researchers at Karolinska Institutet in Sweden...
Regeneron Pharmaceuticals announced positive initial data from the company's ongoing Phase III trial of the antibody cocktail, REGEN-COV, as a passive vaccine to prevent Covid-19 in people...
Shares of Moderna spiked 12.2% after the biotech company said that laboratory studies suggested that its COVID-19 vaccine should be effective against the emerging variants
A biologist explains what proteins do in viruses, how they interact with human cells, how the vaccine delivers mRNA into the cell and how antibodies protect...
The EU has hit back at AstraZeneca’s plan to provide fewer doses of its COVID-19 vaccine than expected, The post EU eyes tighter COVID-19 vaccine exports...
Moderna started development on a booster to the company's Covid-19 vaccine, which is hoped to work against the recently discovered, immunity affecting, SARS-CoV-2 variant from South...
Credit: @Science China Press In the past 20 years, humans have suffered several serious epidemics from emerging viruses, such as SARS, swine flu, Ebola, MERS and...
Merck is stopping development of the company's two Covid-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given...
New Jersey-based Merck has just abandoned its two experimental COVID-19 vaccine projects after early data showed they generated weak immune response.
Cambridge study finds blood markers that could help predict, very early in the disease, who will get severe COVID.
Nearly pain-free microneedle patch can test for antibodies and more in the fluid between cells Credit: Image: Sisi Cao Blood draws are no fun. They hurt....
With the Pfizer-BioNTech and Moderna Covid-19 vaccines authorized in the United States and being distributed and dosed, some of the attention is shifting to Johnson &...
Phase 3 Trial Showed Eli Lilly’s bamlanivimab significantly reduced Covid-19 risk for nursing home residents
The 72-year-old patient was unable to mount her own immune defense against the SARS-CoV-2 virus because of chronic lymphocytic leukemia, which compromises normal immunity and immunoglobulin...
New research highlights the enormous variability in how T cells respond to the deadly virus Credit: La Jolla Institute for Immunology LA JOLLA, CA–A big question...
Vaccines that use harmless viruses as a delivery mechanism are vulnerable to being attacked by our immune system – but experimenting with how they are given...
The new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may...
The Covid-19 vaccine developed by Pfizer and BioNTech is likely to protect against a more infectious variant of the virus discovered in Britain according to results...